Beiersdorf Shifted Strategy After NIVEA Sales Declined
The firm is repositioning its core NIVEA brand toward lower price points as its derma division expands.
Updated on Oct. 9, 2026 in Business Strategy
Live Poll
Do you feel it is a good time to keep purchasing premium brands for daily skincare?
Beiersdorf reported a 6.8% organic sales decline for its NIVEA and Labello brands during the first half of 2026, totaling €2.703 billion. The company responded by launching an 18-month turnaround plan to stabilize the core portfolio.
Why it matters
NIVEA struggled with commercial disputes and inventory reductions, while the company's Eucerin and Aquaphor division thrived through science-based product positioning. Operators must track how these divergent brand performances force changes in marketing spend and product distribution.
NIVEA and Labello sales hit €2.703 billion in the first half of 2026, while the company pledged a €100 million increase in consumer-facing investment for the second half of the year. The group now targets a minimum EBIT margin of 11.8% for 2026.
The players
Beiersdorf
A German-based multinational consumer goods company that manufactures personal care products including NIVEA, Eucerin, and Aquaphor.
The details
Beiersdorf is shifting NIVEA toward more affordable mid- and lower-price segments to address recent performance issues. Simultaneously, the company is leveraging scientific branding to push Eucerin and Aquaphor into new markets, achieving high-double-digit growth in Brazil, China, and the U.S. during the second quarter of 2026.
Timeline
NIVEA and Labello organic sales declined 6.8% in the first half of 2026.
Derma sales in Brazil and China grew significantly during the second quarter of 2026.
Aquaphor launched a new line of body lotions and creams in July 2026.
Beiersdorf will increase consumer-facing investment in the second half of 2026.
Nationwide distribution of the new Aquaphor range is scheduled for the end of 2026.
Market Landscape
Beiersdorf's maneuver follows the 2026 corporate portfolio restructuring cycle, where major firms bifurcate operations to protect growth units from mature-brand stagnation. This divergence highlights a trend of separating scientific derma products from traditional mass-market retail inventory.
Operators should monitor whether their own supply chains are overly exposed to mature products facing inventory consolidation. The shift suggests that premium-priced scientific products remain resilient, while mass-market commodity goods require aggressive price-segment repositioning.
The takeaway
Brand managers should evaluate whether their portfolio requires a similar bifurcation between scientific growth products and value-positioned commodities. Use this transition as a prompt to audit inventory levels for segments that are currently seeing reduced retail shelf-space.
Further reading
For more on how shifts in consumer demand dictate long-term planning, see Business Strategy.
Source note: This article includes information reported by Merca2.0 Magazine.
Live Poll
Do you feel it is a good time to keep purchasing premium brands for daily skincare?
